SavedAdd your journal

Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 4

Clinical and serological characteristics of systemic sclerosis: Experience of a tertiary care center in Pakistan

Zia Ud Din
Muhammad Haroon
Sadia Asif
Asadullah Khan
Muhammad Faiq
Sarmad Zahoor
Pages
587–594
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Pulmonary hypertension was present in 18 patients with a significantly higher prevalence in diffuse disease (57.1%) than limited disease (11.8%) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the clinical and serological characteristics of systemic sclerosis (SSc) in Pakistani population.
📊
Key Findings & Data:Patients and methods: This prospective, cross-sectional study included a total of 38 patients (6 males, 32 females; mean age: 34.5±1.5 years; range, 16 to 60 years) with SSc who were admitted to our rheumatology clinic between November 2019 and January 2020.
💡
Conclusion & Impact:Pulmonary hypertension was present in 18 patients with a significantly higher prevalence in diffuse disease (57.1%) than limited disease (11.8%) (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to evaluate the clinical and serological characteristics of systemic sclerosis (SSc) in Pakistani population. Patients and methods: This prospective, cross-sectional study included a total of 38 patients (6 males, 32 females; mean age: 34.5±1.5 years; range, 16 to 60 years) with SSc who were admitted to our rheumatology clinic between November 2019 and January 2020. We evaluated the clinical, serological, and radiological features of SSc patients. Results: Thirty-four (89.5%) patients developed Raynaud phenomenon at the time of disease onset, while sclerodactyly was found in 34 (89.5%), digital ulcers in 25 (65.8%), and tendon friction rub in 12 (31.6%) patients. Interstitial lung disease was present in 30 (78.9%) patients with a higher prevalence in diffuse scleroderma (100%) than in limited scleroderma (70%) (p=0.01). Pulmonary hypertension was present in 18 patients with a significantly higher prevalence in diffuse disease (57.1%) than limited disease (11.8%) (p

🔖

Cite This Article

Din, Z. U., Haroon, M., Asif, S., Khan, A., Faiq, M., Zahoor, S. (2022). Clinical and serological characteristics of systemic sclerosis: Experience of a tertiary care center in Pakistan. Archives of Rheumatology, Cilt: 36 - Sayı: 4, 587–594. https://ajindex.com/articles/448011

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis - multidisciplinary disease: Clinical features and treatment. Reumatologia 2019;57:221-33
  2. Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol 2018;37:2103-11
  3. Yamamoto T. Scleroderma--pathophysiology. Eur J Dermatol 2009;19:14-24. 4. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47
  4. Arkachaisri T, Fertig N, Pino S, Medsger TA Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 2008;35:2439-44
  5. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6
  6. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study. QJM 2010;103:109-15
  7. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42
  8. Al-Adhadh RN, Al-Sayed TA. Clinical features of systemic sclerosis. Saudi Med J 2001;22:333-6
  9. Ghosh SK, Bandyopadhyay D, Saha I, Barua JK. Mucocutaneous and demographic features of systemic sclerosis: A profile of 46 patients from eastern India. Indian J Dermatol 2012;57:201-5
  10. Carreira PE, Carmona L, Joven BE, Loza E, Andréu JL, Riemekasten G, et al. Differences associated with age at onset in early systemic sclerosis patients: A report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database. Scand J Rheumatol 2019;48:42-51
  11. Coi A, Barsotti S, Santoro M, Almerigogna F, Bargagli E, Caproni M, et al. Epidemiology of systemic sclerosis: A multi-database population-based study in Tuscany (Italy). Orphanet J Rare Dis 2021;16:90
  12. Shanmugam VK, Frech TM, Steen VD, Hummers LK, Shah AA, Bernstein EJ, et al. Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: Outcomes from a multicenter US-based systemic sclerosis registry. Clin Rheumatol 2020;39:93-102
  13. Walker UA, Tyndall A, Czirják L, Denton C, FargeBancel D, Kowal-Bielecka O, et al. Cl